ClinicalTrials.gg
CompletedNCT02266537Updated Oct 17, 2014

Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

A Phase 1 interventional study of Tamsulosin and Alfuzosin in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-17.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
Male
01

Study summary

The study was aimed to evaluate the pharmacological effect of different α-antagonists on phenylephrine induced pupil size in healthy male volunteers as pharmacological basis for Intraoperative floppy iris syndrome (IFIS)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male
  • Age ≥ 21 and ≤ 55 years
  • (BMI) ≥ 18.5 and ≤ 29.9 kg/m2
  • Signed and dated written in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and (ECG)) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24:00 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study or during the study
  • Use of any drugs which might influence the results of the trial up to seven days prior to enrolment in the study or during the study
  • Participation in another trial with an drug (≤ two months prior to administration or during the trial)
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking on in-house trial days
  • Alcohol abuse (> 60 g/day)
  • Drug abuse
  • Blood donation (≥ 100 mL within four weeks prior to administration or during the trial)
  • Any laboratory value outside the clinically accepted reference range
  • Excessive physical activities within the last week before the trial or during the trial

The following exclusion criteria are of special interest for this study:

  • Hypersensitivity to any alpha agonist, or to phenylephrine
  • Supine blood pressure at screening of systolic \< 110 mmHg and diastolic \< 60 mmHg
  • Ophthalmological criteria:

    • Corrected visual acuity \< 0.5
    • Refractive Error with a spherical equivalent > +6 or smaller - 6 D
    • Elevated intraocular pressure (higher than 22 mmHg)
    • Relevant anisocoria or pupil deformation
    • History of eye surgery apart from laser trabeculoplasty less than three months previously or extraocular surgery such as strabismus surgery
    • Topical ocular medication influencing IOP (intraocular pressure) or pupil size within 3 months prior to study-start
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Tamsulosin

    Drug: Tamsulosin

  • Experimental
    Alfuzosin

    Drug: Alfuzosin

  • Experimental
    Doxazosin

    Drug: Doxazosin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Sum of changes from baseline in the mean pupil diameters

    Time frame: Baseline, 60 and 80 min after administration of phenylephrine (PE)

Secondary outcomes

  1. Change from baseline in mean diameter of both pupils

    Time frame: Baseline, 60 and 80 min after administration of phenylephrine (PE)

  2. Change from baseline in mean diameter of both pupils

    Time frame: one week after cessation of drug

  3. Concentration of the analyte in plasma

    Time frame: Up to 29 days after first administration of α-antagonists

  4. Number of participants with clinically significant changes in vital signs

    Time frame: Up to 8 days after last pupillometry

  5. Number of participants with abnormal changes in clinical laboratory parameters

    Time frame: Up to 8 days after last pupillometry

  6. Number of participants with Adverse Events

    Time frame: Up to 8 days after last pupillometry

  7. Assessement of global tolerability by investigator on a 4 point scale

    Time frame: 8 days after last pupillometry

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005 and a primary completion of Feb 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2014
First posted
Oct 17, 2014
Start
Nov 2005
Primary completionActual
Feb 2006
Last update
Oct 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02266537
Responsible party
Sponsor
First posted
Oct 17, 2014
Start date
Nov 2005
Primary completion
Feb 2006
Last update
Oct 17, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamsulosin · Alfuzosin · Doxazosin

Start the discussion